These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 36905489)

  • 1. Engineered fibrotic liver-targeted truncated transforming growth factor β receptor type II variant for superior anti-liver fibrosis therapy.
    Ma M; Wang X; Liu X; Han Y; Chu Y; Guan Y; Liu H
    Arch Pharm Res; 2023 Mar; 46(3):177-191. PubMed ID: 36905489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted truncated TGF-β receptor type II delivery to fibrotic liver by PDGFβ receptor-binding peptide modification for improving the anti-fibrotic activity against hepatic fibrosis in vitro and in vivo.
    Huang Z; Ding M; Dong Y; Ma M; Song X; Liu Y; Gao Z; Guan H; Chu Y; Feng H; Wang X; Liu H
    Int J Biol Macromol; 2021 Oct; 188():941-949. PubMed ID: 34389395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDGFβ receptor-targeted delivery of truncated transforming growth factor β receptor type II for improving the in vitro and in vivo anti-renal fibrosis activity via strong inactivation of TGF-β1/Smad signaling pathway.
    Wang B; Wang X; Dong Y; Liu X; Xu L; Liu Y; Wu Y; Wang C; Liu H
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):237-252. PubMed ID: 37401970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Chimeric Protein BiPPB-mIFNγ-tTβRII for Improving the Anti-Fibrotic Activity in Vivo by Targeting Fibrotic Liver and Dual Inhibiting the TGF-β1/Smad Signaling Pathway.
    Dong Y; Wang X; Xu L; Li X; Dai H; Mao X; Chu Y; Yuan X; Liu H
    Protein J; 2023 Dec; 42(6):753-765. PubMed ID: 37690089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting delivery of a novel TGF-β type I receptor-mimicking peptide to activated hepatic stellate cells for liver fibrosis therapy via inhibiting the TGF-β1/Smad and p38 MAPK signaling pathways.
    Liu X; Wang X; Xu L; Fan J; Yuan Q; Zhang F; Liu J; Qiu X; Li Y; Xia C; Liu H
    Eur J Pharmacol; 2024 Aug; 977():176708. PubMed ID: 38843945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression, purification, and evaluation of in vivo anti-fibrotic activity for soluble truncated TGF-β receptor II as a cleavable His-SUMO fusion protein.
    Wang X; Li Y; Li X; Yan L; Guan H; Han R; Han Y; Gui J; Xu X; Dong Y; Liu H
    World J Microbiol Biotechnol; 2018 Nov; 34(12):181. PubMed ID: 30474742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of type I TGF-β receptor-mimicking peptide to fibrotic kidney for improving kidney fibrosis therapy via enhancing the inhibition of TGF-β1/Smad and p38 MAPK pathways.
    Wang X; Liu X; Xu L; Li Y; Zheng B; Xia C; Wang J; Liu H
    Int Immunopharmacol; 2024 Aug; 137():112483. PubMed ID: 38880023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling.
    Xiang D; Zou J; Zhu X; Chen X; Luo J; Kong L; Zhang H
    Phytomedicine; 2020 Nov; 78():153294. PubMed ID: 32771890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymosin β4 suppresses CCl
    Li H; Li Q; Zhang X; Zheng X; Zhang Q; Hao Z
    J Gene Med; 2018 Sep; 20(9):e3043. PubMed ID: 29972714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFβR bicyclic peptide inhibits liver fibrogenesis in vivo.
    Bansal R; Prakash J; De Ruiter M; Poelstra K
    PLoS One; 2014; 9(2):e89878. PubMed ID: 24587093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oral phenylacrylic acid derivative suppressed hepatic stellate cell activation and ameliorated liver fibrosis by blocking TGF-β1 signalling.
    Xue T; Yue L; Zhu G; Tan Z; Liu H; Gan C; Fan C; Su X; Xie Y; Ye T
    Liver Int; 2023 Mar; 43(3):718-732. PubMed ID: 36448910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DCDC2 inhibits hepatic stellate cell activation and ameliorates CCl
    Liu QQ; Chen J; Ma T; Huang W; Lu CH
    Sci Rep; 2024 Apr; 14(1):9425. PubMed ID: 38658618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone morphogenetic protein-7 represses hepatic stellate cell activation and liver fibrosis
    Zou GL; Zuo S; Lu S; Hu RH; Lu YY; Yang J; Deng KS; Wu YT; Mu M; Zhu JJ; Zeng JZ; Zhang BF; Wu X; Zhao XK; Li HY
    World J Gastroenterol; 2019 Aug; 25(30):4222-4234. PubMed ID: 31435175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The common dietary flavonoid myricetin attenuates liver fibrosis in carbon tetrachloride treated mice.
    Geng Y; Sun Q; Li W; Lu ZM; Xu HY; Shi JS; Xu ZH
    Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27983763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant truncated latency-associated peptide alleviates liver fibrosis in vitro and in vivo via inhibition of TGF-β/Smad pathway.
    Song X; Shi J; Liu J; Liu Y; Yu Y; Qiu Y; Cao Z; Pan Y; Yuan X; Chu Y; Wu D
    Mol Med; 2022 Jul; 28(1):80. PubMed ID: 35842576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation, apoptosis, cell cycle, and ECM-receptor interaction mediated by TGF-β/Smad signaling.
    Chen C; Chen J; Wang Y; Fang L; Guo C; Sang T; Peng H; Zhao Q; Chen S; Lin X; Wang X
    Phytomedicine; 2023 Feb; 110():154626. PubMed ID: 36603342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligo-peptide I-C-F-6 inhibits hepatic stellate cell activation and ameliorates CCl
    Sun H; Chen G; Wen B; Sun J; An H; Pang J; Xu W; Yang X; He S
    J Pharmacol Sci; 2018 Mar; 136(3):133-141. PubMed ID: 29501581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morin attenuates diethylnitrosamine-induced rat liver fibrosis and hepatic stellate cell activation by co-ordinated regulation of Hippo/Yap and TGF-β1/Smad signaling.
    Perumal N; Perumal M; Halagowder D; Sivasithamparam N
    Biochimie; 2017 Sep; 140():10-19. PubMed ID: 28552397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-β1/SMAD Signaling and Autophagy in Hepatic Stellate Cells.
    Kataoka S; Umemura A; Okuda K; Taketani H; Seko Y; Nishikawa T; Yamaguchi K; Moriguchi M; Kanbara Y; Arbiser JL; Shima T; Okanoue T; Itoh Y
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARγ/NF-κB and TGF-β1/Smad pathway are involved in the anti-fibrotic effects of levo-tetrahydropalmatine on liver fibrosis.
    Yu Q; Cheng P; Wu J; Guo C
    J Cell Mol Med; 2021 Feb; 25(3):1645-1660. PubMed ID: 33438347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.